Clinical trials: Respiratory Virus Infection
Influenza Virus
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to <72 Months of Age.
- Trial name
- NCT01964989
- Testing
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
- Where
- 167 sites in United States, Canada and 9 more
- Volunteers
- 10,644 people, healthy volunteers welcome
- Sponsor
- Seqirus
Diphtheria, Tetanus
Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine
The objective of this study is to compare the Safety and Immunogenicity of a mixed sequence of 2 different pentavalent vaccines (Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib combination Vaccines) with single sequence of…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00674908
- Testing
- Shan 5, Easy Five
- Where
- 3 sites in India
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Shantha Biotechnics Limited
Acute Respiratory Viral Infection
Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.
- Trial name
- NCT06715891
- Testing
- Raphamin
- Where
- 35 sites in Russia
- Volunteers
- 374 people
- Sponsor
- Materia Medica Holding
Influenza
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.
- Trial name
- NCT05523089
- Testing
- CD388
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Respiratory Viral Infections, Influenza
Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221 vs.
- Trial name
- NCT03455491
- Testing
- XC221 100 mg, XC221 200 mg
- Where
- 11 sites in Russia
- Volunteers
- 120 people
- Sponsor
- PHARMENTERPRISES LLC
COVID-19, SARS-CoV-2
NOWDx Test for the Detection of Antibodies to COVID-19
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device.
- Conditions
- COVID-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04690413
- Testing
- NOWDx COVID-19 Test
- Where
- 3 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- NOWDiagnostics, Inc.
Respiratory Syncytial Virus Infections
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
The purpose of this study is to assess the lot-to-lot consistency in terms of immunogenicity and evaluate the safety and reactogenicity of 3 lots of the RSVPreF3 OA investigational vaccine administered as a single dose in adults…
- Trial name
- NCT05059301
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis, Diphtheria
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Post-marketing evaluation of reactions following receipt of recommended adolescent pertussis vaccine among persons with prior vaccination with acellular vs whole-cell pertussis vaccine.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00304265
- Testing
- COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
- Where
- 17 sites in Germany
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients.
- Trial name
- NCT01825200
- Testing
- Flublok, Afluria
- Where
- 14 sites in United States
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Severe Sepsis
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05665153
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bluejay Diagnostics, Inc.
COVID-19
The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin
This study is a multi-center, randomized, double blinded, prospective, placebo controlled study. Patients upon diagnosis of COVID-19 (Corona Virus Disease-19) will be eligible to participate in the study.
- Trial name
- NCT04601077
- Testing
- Nitric Oxide lozenges, 30 mg
- Where
- United States
- Volunteers
- 524 people
- Sponsor
- Nitric Oxide Innovations LLC
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02831751
- Testing
- 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain)
- Where
- 15 sites in United States, Canada
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Medicago
Immunization, Human Influenza
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization
The purpose of this study is to determine whether Yili Lactoferrin ShuHua Milk are effective in reducing the occurrence of flu symptoms.
- Conditions
- Immunization, Human Influenza, Common Cold
- Trial name
- NCT01677702
- Testing
- Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml), Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml), Recombined low protein milk
- Where
- 2 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Inner Mongolia Yili Industrial Group Co., Ltd
Respiratory Syncytial Virus (RSV)
A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.
Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies.
- Trial name
- Amélie (NCT06473519)
- Testing
- RSVpreF MDV, RSVpreF SDV
- Where
- 6 sites in United States
- Volunteers
- 453 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Immunogenicity and Safety of GSK Biologicals' FluLaval® TF
The present study is intended to assess a novel formulation of FluLaval. The idea is to obtain preliminary data on the safety and immune response to the FluLaval TF influenza vaccine in adults.
- Trial name
- NCT00727428
- Testing
- FluLaval® TF
- Where
- Belgium
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic Influenza
A/H5N1 Dose Ranging Study With Adjuvant Patch
This is a Phase 1/2, randomized, observer-blind, placebo-controlled clinical trial. A maximum of 500 eligible subjects in 10 groups will be enrolled, randomized and vaccinated in this study.
- Trial name
- NCT00532792
- Testing
- A/H5N1
- Where
- 5 sites in United States
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Covid-19
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
- Trial name
- SOC (NCT04440007)
- Testing
- Abivertinib, Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
This is a Phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal STI-9199 in adults and adolescents who are COVID-19 positive with mild to…
- Trial name
- NCT05372783
- Testing
- STI-9199
- Where
- United States
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04758273
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
To evaluate the safety of a single intramuscular (IM) injection of trivalent nonadjuvated influenza study vaccine, formulation 2012/2013, in adult and elderly subjects and the antibody response to each influenza vaccine antigen…
- Trial name
- NCT01636102
- Testing
- Trivalent influenza virus vaccine (TIV)
- Where
- Belgium
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.